Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide

Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide

Abstract Cytokine release syndrome (CRS) represents a life‐threatening side effect after haploidentical stem cell transplantation (Haplo‐SCT) with posttransplant cyclophosphamide (PT‐Cy). Factors predictive of CRS development is still a matter of debate. We retrospectively analyzed 102 consecutive p...

Full description

Bibliographic Details
Main Authors: Jacopo Mariotti, Daniela Taurino, Fabrizio Marino, Stefania Bramanti, Barbara Sarina, Lucio Morabito, Chiara De Philippis, Clara Di Vito, Domenico Mavilio, Carmelo Carlo‐Stella, Matteo Della Porta, Armando Santoro, Luca Castagna
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Cancer Medicine
Subjects:
cytokine release syndrome
disease burden
haploidentical stem cell transplant with posttransplant cyclophosphamide
HLA mismatch
Online Access:https://doi.org/10.1002/cam4.2607

Internet

https://doi.org/10.1002/cam4.2607

Similar Items